Rezolute, Inc.
NASDAQ:RZLT
5.24 (USD) • At close January 3, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Rezolute, Inc. |
Symbool | RZLT |
Munteenheid | USD |
Prijs | 5.24 |
Beurswaarde | 303,621,844 |
Dividendpercentage | 0% |
52-weken bereik | 0.9 - 6.186 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Nevan Charles Elam J.D. |
Website | https://www.rezolutebio.com |
An error occurred while fetching data.
Over Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)